106 related articles for article (PubMed ID: 38760553)
1. FOXO1 enhances CAR T cell fitness and function.
Marchal I
Nat Biotechnol; 2024 May; 42(5):699. PubMed ID: 38760553
[No Abstract] [Full Text] [Related]
2. FOXO1 is a master regulator of memory programming in CAR T cells.
Doan AE; Mueller KP; Chen AY; Rouin GT; Chen Y; Daniel B; Lattin J; Markovska M; Mozarsky B; Arias-Umana J; Hapke R; Jung IY; Wang A; Xu P; Klysz D; Zuern G; Bashti M; Quinn PJ; Miao Z; Sandor K; Zhang W; Chen GM; Ryu F; Logun M; Hall J; Tan K; Grupp SA; McClory SE; Lareau CA; Fraietta JA; Sotillo E; Satpathy AT; Mackall CL; Weber EW
Nature; 2024 May; 629(8010):211-218. PubMed ID: 38600391
[TBL] [Abstract][Full Text] [Related]
3. FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy.
Chan JD; Scheffler CM; Munoz I; Sek K; Lee JN; Huang YK; Yap KM; Saw NYL; Li J; Chen AXY; Chan CW; Derrick EB; Todd KL; Tong J; Dunbar PA; Li J; Hoang TX; de Menezes MN; Petley EV; Kim JS; Nguyen D; Leung PSK; So J; Deguit C; Zhu J; House IG; Kats LM; Scott AM; Solomon BJ; Harrison SJ; Oliaro J; Parish IA; Quinn KM; Neeson PJ; Slaney CY; Lai J; Beavis PA; Darcy PK
Nature; 2024 May; 629(8010):201-210. PubMed ID: 38600376
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy.
Klebanoff CA; Crompton JG; Leonardi AJ; Yamamoto TN; Chandran SS; Eil RL; Sukumar M; Vodnala SK; Hu J; Ji Y; Clever D; Black MA; Gurusamy D; Kruhlak MJ; Jin P; Stroncek DF; Gattinoni L; Feldman SA; Restifo NP
JCI Insight; 2017 Dec; 2(23):. PubMed ID: 29212954
[TBL] [Abstract][Full Text] [Related]
5. CAR T Cells Releasing IL-18 Convert to T-Bet
Chmielewski M; Abken H
Cell Rep; 2017 Dec; 21(11):3205-3219. PubMed ID: 29241547
[TBL] [Abstract][Full Text] [Related]
6. Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective.
Han C; Kwon BS
Immunotherapy; 2018 Mar; 10(3):221-234. PubMed ID: 29370727
[TBL] [Abstract][Full Text] [Related]
7. Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy.
Ghassemi S; Milone MC
J Vis Exp; 2019 Dec; (154):. PubMed ID: 31904011
[TBL] [Abstract][Full Text] [Related]
8. Senolytic CAR T Cells in Solid Tumors and Age-Related Pathologies.
Feucht J; Abou-El-Enein M
Mol Ther; 2020 Oct; 28(10):2108-2110. PubMed ID: 32841587
[No Abstract] [Full Text] [Related]
9. CD70 CAR T cells in AML: Form follows function.
Mirazee J; Shah NN
Cell Rep Med; 2022 May; 3(5):100639. PubMed ID: 35584621
[TBL] [Abstract][Full Text] [Related]
10. CAR T-cells for relapsed B-cell ALL in adults.
Gilbert JA
Lancet Oncol; 2018 Mar; 19(3):e143. PubMed ID: 29429915
[No Abstract] [Full Text] [Related]
11. CAR T cells for solid tumors - developments to watch in 2023.
Trefny MP; Kobold S
Expert Opin Biol Ther; 2024 Apr; 24(4):207-211. PubMed ID: 38526025
[No Abstract] [Full Text] [Related]
12. Construction of a chimeric antigen receptor bearing a nanobody against prostate a specific membrane antigen in prostate cancer.
Hassani M; Hajari Taheri F; Sharifzadeh Z; Arashkia A; Hadjati J; van Weerden WM; Modarressi MH; Abolhassani M
J Cell Biochem; 2019 Jun; 120(6):10787-10795. PubMed ID: 30672018
[TBL] [Abstract][Full Text] [Related]
13. CAR T-cell therapy for solid tumours.
The Lancet Oncology
Lancet Oncol; 2021 Jul; 22(7):893. PubMed ID: 34197740
[No Abstract] [Full Text] [Related]
14. Generation of CAR-T Cells for Cancer Immunotherapy.
Xu Q; Harto H; Berahovich R; Xu S; Zhou H; Golubovskaya V; Wu L
Methods Mol Biol; 2019; 1884():349-360. PubMed ID: 30465215
[TBL] [Abstract][Full Text] [Related]
15. [Application of mRNA nano-delivery system in CAR-T tumor immunotherapy].
Zeng Y; Wei S; Sun J; Xu N
Sheng Wu Gong Cheng Xue Bao; 2024 May; 40(5):1338-1351. PubMed ID: 38783801
[TBL] [Abstract][Full Text] [Related]
16. Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy.
Ti D; Niu Y; Wu Z; Fu X; Han W
Sci China Life Sci; 2018 Nov; 61(11):1320-1332. PubMed ID: 30414005
[TBL] [Abstract][Full Text] [Related]
17. Cas13d-mediated gene knockdown in CAR T cells: towards off-the-shelf cancer treatment.
Johnston M; Urban N; Dincer C
Signal Transduct Target Ther; 2024 Apr; 9(1):113. PubMed ID: 38670950
[No Abstract] [Full Text] [Related]
18. Navigating CAR-T cells through the solid-tumour microenvironment.
Hou AJ; Chen LC; Chen YY
Nat Rev Drug Discov; 2021 Jul; 20(7):531-550. PubMed ID: 33972771
[TBL] [Abstract][Full Text] [Related]
19. Cancer-fighting CAR T cells could be made inside body with viral injection.
Ledford H
Nature; 2024 Jan; 625(7994):225-226. PubMed ID: 38129613
[No Abstract] [Full Text] [Related]
20. FOXO1 Inhibition Generates Potent Nonactivated CAR T Cells against Solid Tumors.
Marchais M; Simula L; Phayanouvong M; Mami-Chouaib F; Bismuth G; Decroocq J; Bouscary D; Dutrieux J; Mangeney M
Cancer Immunol Res; 2023 Nov; 11(11):1508-1523. PubMed ID: 37649096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
